CAJ | 학술논문

嵌合抗原受体修饰淋巴细胞是过继免疫治疗的一种类型，其通过体外改造细胞表面受体，使淋巴细胞过表达，从而促进淋巴细胞的抗肿瘤活性。这种技术是目前恶性肿瘤免疫治疗领域中的新疗方法之一，在恶性血液病尤其是B细胞系统恶性血液病中治疗效果令人振奋。多发性骨髓瘤是血液系统第二常见恶性肿瘤，好发于老年人，目前仍无法治愈，研究者们一直在探索该病的免疫治疗。本文对近年来嵌合抗原受体修饰淋巴细胞技术的发展及其在多发性骨髓瘤中的应用进行综述。
감합항원수체수식림파세포시과계면역치료적일충류형，기통과체외개조세포표면수체，사림파세포과표체，종이촉진림파세포적항종류활성。저충기술시목전악성종류면역치료영역중적신료방법지일，재악성혈액병우기시B세포계통악성혈액병중치료효과령인진강。다발성골수류시혈액계통제이상견악성종류，호발우노년인，목전잉무법치유，연구자문일직재탐색해병적면역치료。본문대근년래감합항원수체수식림파세포기술적발전급기재다발성골수류중적응용진행종술。
Chimeric antigen receptor-modified lymphocyte is a type of cancer immunotherapies. By re-engineering antigen receptor in vitro, it can be expressed on the membrane of lymphocytes and increase the function of killing cancer cells. It is now the most attractivefield of cancer immunotherapies in hematologic malignancies, especially in B-cell malignancies by its significant therapeutic effect. Multiple myeloma (MM) is the second common hematologic cancer in the elderly populations. Up to now, it is still incurable. Researchers have been exploring the applications of immunotherapy in MM. This review discusses the recent development of chimeric antigen receptor-modified lymphocytic cell technology and its application in multiple myeloma.